<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Coronary artery stent thrombosis: Incidence and risk factors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Coronary artery stent thrombosis: Incidence and risk factors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Coronary artery stent thrombosis: Incidence and risk factors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald Cutlip, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Dawn Abbott, MD, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher P Cannon, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephan Windecker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coronary artery stents are used in the majority of patients who undergo percutaneous coronary intervention (PCI), as they significantly reduce the need for repeat target vessel revascularization compared to balloon angioplasty. (See
         <a class="medical medical_review" href="/z/d/html/1587.html" rel="external">
          "Intracoronary stent restenosis", section on 'Incidence of restenosis'
         </a>
         .)
        </p>
        <p>
         Stent thrombosis is an uncommon but serious complication that almost always presents as death or a large non-fatal myocardial infarction (MI), usually with ST elevation. It is estimated that less than 10 percent of cardiac deaths after stent placement are attributable to stent thrombosis, with most of the remainder being due to disease progression [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Stent thrombosis can occur acutely (within 24 hours), subacutely (within 30 days), or as late as one year (late) or more (very late) after stent placement. Stent thrombosis within the first year appears to occur with similar frequency in patients with bare metal stents (BMS) or drug-eluting stents (DES), as long as patients are treated with dual antiplatelet therapy (
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         plus a platelet P2Y
         <sub>
          12
         </sub>
         receptor blocker) for the recommended duration. The period of risk requiring dual antiplatelet therapy (DAPT) is longer with DES, due at least in part to delayed neointimal coverage, although this difference is decreasing with newer generation DES. (See
         <a class="local">
          'Very late stent thrombosis'
         </a>
         below.)
        </p>
        <p>
         General issues related to stent thrombosis will be reviewed in this topic. The prevention and management of stent thrombosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">
          "Long-term antiplatelet therapy after coronary artery stenting in stable patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87310.html" rel="external">
          "Coronary artery stent thrombosis: Clinical presentation and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although earlier clinical trials posed a problem for comparing stent thrombosis rates due to non-standardized definition, since 2007 most trials have adopted the criteria and classification proposed by the Academic Research Consortium (ARC) [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definite
         </strong>
         – Angiographic confirmation of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent, with or without vessel occlusion, which is associated with acute onset of ischemic symptoms at rest or ECG signs of acute ischemia or typical rise and fall of in cardiac biomarkers within 48 hours of angiography
         <strong>
          OR
         </strong>
         pathologic confirmation of stent thrombosis determined at autopsy or from tissue obtained following thrombectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Probable
         </strong>
         – Unexplained death occurring within 30 days after the index procedure, or an MI occurring at any time after the index procedure that was documented by ECG or imaging to occur in an area supplied by the stented vessel in the absence of angiographic confirmation of stent thrombosis or other culprit lesion.
        </p>
        <p>
        </p>
        <p>
         In the discussion that follows, studies using definitions other than ARC will be noted.
        </p>
        <p class="headingAnchor" id="H176751508">
         <span class="h1">
          INTRAPROCEDURAL STENT THROMBOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraprocedural stent thrombosis (IPST) is the development of occlusive or non-occlusive new or increasing thrombus in or adjacent to a recently implanted stent before the percutaneous coronary intervention (PCI) procedure is completed [
         <a href="#rid4">
          4,5
         </a>
         ]. IPST is not included in the academic research consortium definitions discussed above. In one rigorous study of IPST, it was further defined as any discrete, mobile, intraluminal filling defect, with defined borders, with or without associated contrast staining or a total occlusion with convex edges and staining [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Intraprocedural stent thrombosis, by definition, occurs sometime after an intracoronary stent is deployed and before the end of the PCI. The best available data on its incidence come from an analysis of events in the CHAMPION PHOENIX trial, which compared
         <a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">
          cangrelor
         </a>
         to
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         in patients undergoing PCI [
         <a href="#rid5">
          5
         </a>
         ]. Among 10,939 patients included in the study, IPST developed in 0.8 percent. Similar incidences have been reported in other smaller series [
         <a href="#rid4">
          4,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'Cangrelor'
         </a>
         .)
        </p>
        <p>
         The risk of IPST is significantly increased in patients with one or more of the following characteristics: ST- or non-ST elevation myocardial infarction (MI) (both compared with stable angina), thrombus at baseline, and bifurcation lesions [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         The clinical presentation and management of IPST is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/87310.html" rel="external">
          "Coronary artery stent thrombosis: Clinical presentation and management", section on 'Intraprocedural stent thrombosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          MECHANISMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for the development of stent thrombosis fall into broad categories of procedural, patient, lesion, and stent characteristics as well as the cessation of antiplatelet therapy [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Risk factors'
         </a>
         below.)
        </p>
        <p>
         Each risk factor is likely to predispose the patient to stent thrombosis, which is characterized by platelet activation and aggregation, by one or more of the following mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent slow coronary blood flow (local or arterial) as occurs with dissection or hypoperfusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior to reendothelialization, exposure of the blood to prothrombotic subendothelial constituents, such as tissue factor, or to the stent itself.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to suppress platelet adhesion/aggregation at a time of prothrombotic risk, as occurs with premature cessation of antiplatelet therapy or drug resistance.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          TIMING AND INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of stent thrombosis, occur within the first 30 days after placement, irrespective of stent type [
         <a href="#rid8">
          8
         </a>
         ]. Reported rates tend to be lower in clinical trials (or meta-analyses of clinical trials) than in registries, as trials often enroll lower risk patients. In general, we tell our patients that the rate of stent thrombosis at one year is about one percent and that the yearly rate following one year is about 0.2 percent per year.
        </p>
        <p>
         Most of the data for drug-eluting stent (DES) thrombosis across populations with a broad range of risk come from multiple registries in the era of first generation DES:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Bern-Rotterdam registry, 8146 patients underwent PCI with a sirolimus- or a paclitaxel-eluting stent (SES or PES). At three years, the cumulative incidence of angiographic stent thrombosis was 2.9 percent, with early (acute and subacute) stent thrombosis occurring in 60 percent and late stent thrombosis (all events after 30 days) in 40 percent [
         <a href="#rid9">
          9
         </a>
         ]. After one year, the rate of stent thrombosis was 0.6 percent per year.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), 42,150 patients underwent PCI with either bare metal or drug-eluting stents [
         <a href="#rid10">
          10
         </a>
         ]. During a mean follow-up of 661 days, the rate of definite stent thrombosis was 1.2 percent, of which 50 percent were acute or subacute. The rate after one year appeared constant out to three years at about 0.3 to 0.4 percent per year.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Dutch stent thrombosis registry, 21,009 underwent PCI with either bare metal or drug-eluting stents [
         <a href="#rid11">
          11
         </a>
         ]. During a median follow-up of 31 months, ARC definite stent thrombosis was present in 2.1 percent of which 32 percent was acute, 41 percent subacute, 13 percent late and 14 percent very late.
        </p>
        <p>
        </p>
        <p>
         These data are limited by the restriction to first generation DES. (See
         <a class="local">
          'Comparison of differing DES'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Bare metal stents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bare metal stent (BMS) thrombosis usually occurs within the first 24 to 48 hours (acute) or much less often within the first month (subacute) after stent placement [
         <a href="#rid12">
          12-20
         </a>
         ]. In a pooled analysis of data from stent trials registries, stent thrombosis developed in 0.9 percent by 30 days and approximately 80 percent of these occurred within the first two days [
         <a href="#rid14">
          14
         </a>
         ]. The incidence of stent thrombosis by 30 days has ranged between 0.5 to 2.5 percent with higher rates in patient populations at higher risk [
         <a href="#rid12">
          12,13,21
         </a>
         ].
        </p>
        <p>
         Thrombotic events with BMS are uncommon after 30 days of treatment with dual antiplatelet therapy [
         <a href="#rid11">
          11,22-24
         </a>
         ]. This observation is consistent with angioscopic studies that showed complete re-endothelialization by three to six months [
         <a href="#rid25">
          25,26
         </a>
         ]. In a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) of over 94,000 stent implantations, the cumulative incidence of stent thrombosis with BMS at one year was approximately 1.1 percent [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Very late stent thrombosis (after one year) is uncommonly seen with BMS and is often after a repeat procedure has been performed in the stented segment. In SCAAR, the rate of definite stent thrombosis at two years was 1.4 percent [
         <a href="#rid27">
          27
         </a>
         ]. In our experience of adjudicating late and very late stent thrombosis after BMS, it is often difficult to determine the contributing role of restenosis.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Drug-eluting stents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rates of stent thrombosis, particularly after one year, are lower with new-generation compared with first-generation DES [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Similar to BMS, most episodes of drug-eluting stent thrombosis occur in the first year and many of these within the first 30 days. In a meta-analysis of 10 randomized trials of 5030 patients comparing PES or SES (first generation DES) to BMS, the 30-day rate of stent thrombosis (ST) in patients receiving DES was 0.58 percent [
         <a href="#rid21">
          21
         </a>
         ]. In a report of over 94,000 stent implantations in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the cumulative incidence of stent thrombosis with DES at one year was approximately 0.4 to 0.8 percent [
         <a href="#rid27">
          27
         </a>
         ]. In a 2006 meta-analysis of 19 randomized trials with 7060 patients, the risk of PES or SES thrombosis was 0.7 percent with one-year follow-up [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Events continue after one year (very late stent thrombosis) for at least five years. In clinical trial populations, the risk has been estimated at 0.2 to 0.3 percent per year after the first year [
         <a href="#rid30">
          30
         </a>
         ], but a number of studies have demonstrated the risk beyond one year is higher (as much as 0.6 percent per year) in routine practice settings [
         <a href="#rid10">
          10,31-34
         </a>
         ]. Ongoing inflammation and delayed healing with first generation DES were largely responsible for this higher risk of very late stent thrombosis. Much of the safety benefit for newer generation DES is due to the reduction in these very late events. (See
         <a class="local">
          'Very late stent thrombosis'
         </a>
         below and
         <a class="local">
          'Comparison of differing DES'
         </a>
         below.)
        </p>
        <p>
         The following studies illustrate the range of risk beyond one year for patients who received differing DES:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2012 publication from SCAAR, the cumulative rates of definite stent thrombosis at two years for older DES (SES, PES, and the Endeavor zotarolimus [ZES]) and newer DES (
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         and Endeavor Resolute ZES) were 1.3 and 0.6 percent, respectively [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Bern-Rotterdam registry, the annual rate of stent thrombosis was 0.4 to 0.6 percent for up to four years in a population of 8146 individuals who underwent PCI with either SES or PES [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a subsequent report from the Bern-Rotterdam registry (cohort III), the incidence rate of very late stent definite or probable stent thrombosis (ARC definition) per 100 person-years in a cohort of 12,000 patients with unrestricted use of DES (3819 SES, 4308 PES, 4212 EES), for these three DES were 1.6, 2.4, and 0.6 percent, respectively, during follow-up of up to four years.
        </p>
        <p>
        </p>
        <p>
         In the TWENTE trial, which randomly assigned nearly 1400 patients to either ZES or EES, the rate of very late definite or probable stent thrombosis (between 12 and 24 months) was 0.3 percent in both groups [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types", section on 'Everolimus- versus zotarolimus-eluting stents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H165352083">
         <span class="h2">
          Impact of ACS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The intracoronary and systemic prothrombotic environment accompanying an acute coronary syndrome (ACS) has led to concerns regarding a possible increase in the risk of ST compared to patients with stable angina. This concern has been confirmed in analyses of the ACUITY AND TRITON-TIMI 38 trial databases [
         <a href="#rid36">
          36,37
         </a>
         ]. The range of rates of early stent thrombosis (&lt;30 days) in patients with stable angina or an ACS according to the Academic Research Consortium definition (definite or probable) has been summarized as follows [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bare metal stents: 0 to 0.5, 1.4 to 1.6, and 0 to 2.9 percent (stable angina, NSTEMI and STEMI, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-eluting stents: 0.3 to 0.4, 1.2 to 1.9, and 0 to 3.1 percent (stable angina, NSTEMI and STEMI, respectively).
        </p>
        <p>
        </p>
        <p>
         A 2012 meta-analysis of individual patient data from 11 trials found that the long-term (cumulative) rate of stent thrombosis in patients with ACS was not significantly different between first generation DES and BMS (5.8 versus 4.3 percent, respectively) [
         <a href="#rid39">
          39
         </a>
         ]. We interpret the available evidence to suggest that patients with ACS are at greater risk of stent thrombosis than those with stable disease regardless of stent type.
        </p>
        <p>
         In a network meta-analysis of randomized trials comparing first-generation DES, second-generation DES, or BMS in primary PCI for ST-segment elevation MI, second-generation DES was associated with significantly lower incidence of definite stent thrombosis at one year (odds ratio [OR] 0.3; 95% CI 0.11-0.83) and MI (OR 0.3; 95% CI 0.17-0.54) and target vessel revascularization at one year (OR 0.54; 95% CI 0.80-0.98) when compared with BMS [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         All risk factors for stent thrombosis likely work through one or more of the mechanisms discussed above. All of these promote platelet aggregation. (See
         <a class="local">
          'Mechanisms'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Early and late stent thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The single most important predictor of early and late stent thrombosis is absence of platelet P2Y
         <sub>
          12
         </sub>
         receptor blocker therapy at the time of the event [
         <a href="#rid11">
          11
         </a>
         ]. In one report, the hazard ratio for premature discontinuation of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         was greater than 50 at nine months [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         The relationship between cessation of dual antiplatelet therapy (DAPT) and cardiac events after percutaneous coronary intervention was studied using data from 5018 patients in the PARIS registry [
         <a href="#rid42">
          42
         </a>
         ]. At two years, the overall incidence of cessation for any reason was 57.3 percent; the rates of discontinuation (clinician recommended), interruption (stopping for less than 14 days for surgery), and disruption (due to bleeding or noncompliance) were 40.8, 10.5, and 14.4 percent, respectively. Compared with those on DAPT, the hazard ratio for major adverse cardiovascular events (a composite of cardiac death, definite or probable stent thrombosis, spontaneous myocardial infarction, or clinically indicated target lesion revascularization) was significantly higher only for those with disruption (1.50); it was significantly lower for those with discontinuation (0.63). It was nonsignificantly higher for patients with interruption (1.41, 95% CI 0.94-2.12). (See
         <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">
          "Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Patients needing temporary discontinuation'
         </a>
         .) The impact of disruption on the risk of stent thrombosis was greater in the first 30 days compared with after 30 days.
        </p>
        <p>
         However, similar to many other preventative interventions, the optimal use of DAPT does not ensure that a patient will not experience stent thrombosis. For example, in an observational study of over 10,000 patients undergoing drug-eluting stent (DES) placement, those with early stent thrombosis were on DAPT 86 percent of the time and those with late stent thrombosis were on DAPT 57 percent of the time [
         <a href="#rid43">
          43
         </a>
         ]. Similar findings were noted in the PARIS registry, in which 80 percent of the cases of definite or probable stent thrombosis occurred in patients taking DAPT [
         <a href="#rid42">
          42
         </a>
         ]. In these patients, it is likely that one or more predisposing risk factors leading to a prothrombotic environment make it difficult for DAPT to be fully effective. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
         The timing of late (events from one month to one year) or very late stent thrombosis (events after one year) in relation to discontinuation of one or both antiplatelet agents was evaluated in a review of 161 published cases [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'Timing and incidence'
         </a>
         above.) At the time of stent thrombosis, 19 patients were on
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and thienopyridine, 94 were on aspirin only, 33 had aspirin and thienopyridine stopped simultaneously, and 15 had thienopyridine stopped first and then had aspirin discontinued. The following findings were noted in the 142 patients who had discontinued at least one drug:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 33 patients who stopped both antiplatelet agents simultaneously, the median time to stent thrombosis was seven days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 15 patients who had stopped a thienopyridine with no ill effect and then subsequently stopped
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , the median time to stent thrombosis was seven days from the discontinuation of aspirin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the 48 patients who stopped both agents, 75 percent of cases occurred within 10 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 94 patients with prior discontinuation of thienopyridine but on
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , the median time to event was 122 days. In this group, only 6 percent of cases occurred within 10 days.
        </p>
        <p>
        </p>
        <p>
         The causes of and predictors of premature discontinuation were evaluated in a study of 1622 patients who received at least one DES. In 234 patients (14.4 percent), one or both antiplatelet drugs (
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ) were discontinued for at least five consecutive days during the first year after implantation [
         <a href="#rid45">
          45
         </a>
         ]. Clopidogrel, as opposed to aspirin, discontinuation occurred in the majority (11.8 percent). Among the 218 patients who discontinued any agent and in whom the reason for discontinuation was known, the following observations were made:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The major causes of discontinuation were bleeding events or invasive procedures, medical decisions, or patient decision (50 percent, 32 and 18 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among those who discontinued due to bleeding events/invasive procedures, about half of these discontinuations may not have been necessary, as the bleeding was minor or the upcoming procedure was not likely to be associated with major bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who discontinued due to bleeding events/invasive procedures, predictors included renal impairment, prior major hemorrhage, or peripheral artery disease. Long-term anticoagulant therapy, undergoing procedures in a private hospital, and not receiving instructions were causes in those in whom a medical decision was the cause. In patients who stopped of their own accord, being an immigrant, or using psychotropic drugs were predictors.
        </p>
        <p>
        </p>
        <p>
         The best available data on the risk factors for early (≤30 days) definite stent thrombosis in real world populations come from two case-control studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In analysis of the 21,009 patients in the Dutch Stent Thrombosis Registry, of whom 437 (2.1 percent) presented with an ST, the most important risk factors were premature discontinuation of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         therapy (odds ratio [OR] 36.5), under-sizing (OR 13.46), dissection (OR 6.19), TIMI flow post-PCI (OR 5.24), CAD ≥50 percent proximal of the culprit lesion (OR 4.15), malignancy (OR 3.06), no
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         at the time of the procedure (OR 2.82), and left ventricular ejection fraction &lt;30 percent (OR 2.71) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of clinical, angiographic, and genetic factors of ST in 123 patients and 246 controls on dual antiplatelet therapy in a French registry, nongenetic independent correlates of early stent thrombosis (not included in the genetic marker list below) were diabetes mellitus (OR 1.82, 95% CI 1.02-3.24), use of proton pump inhibitors (OR 2.19, 95% CI 1.29-3.75), and higher
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         loading doses (OR 0.73, 95% CI 0.57-0.93) [
         <a href="#rid46">
          46
         </a>
         ]. Significant independent genetic markers were CYP2C19 metabolic status (OR 1.99, 95% CI 1.47-2.69) and the presence of either the ABCB1 3435 TT (OR 2.16, 95% CI 1.21-3.88) or ITGB3 PLA2 carriage (OR 0.52, 95% CI 0.28-0.95) genotype.
        </p>
        <p>
        </p>
        <p>
         Potential risk factors have been proposed from a number of studies
        </p>
        <p>
         [
         <a href="#rid11">
          11,14-17,19,20,23,29,32,37,41,47-54
         </a>
         ]. The cause-and-effect relationship of some factors, such as left ventricular dysfunction, is less certain:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute coronary syndrome (ACS) and proximal left anterior descending coronary artery lesion (for early stent thrombosis) [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="local">
          'Impact of ACS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Side-branch stenting, diabetes mellitus, and end-stage kidney disease (for late stent thrombosis) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incomplete stent expansion. (See
         <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">
          "Percutaneous coronary intervention with intracoronary stents: Overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater stent length.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residual plaque burden and small stent area on intracoronary ultrasound.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small vessel caliber.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residual thrombus or persistent dissection after stent placement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflow or outflow obstruction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subtherapeutic periprocedural anticoagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Left ventricular dysfunction [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonionic contrast media.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cocaine use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emergent stent placement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior brachytherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Post-procedure TIMI flow grade &lt;3.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         at the time of the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CAD ≥50 percent proximal of culprit lesion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of bifurcation lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multivessel disease, as shown in the SYNTAX trial [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High on treatment (oral antiplatelet therapy) platelet reactivity [
         <a href="#rid55">
          55
         </a>
         ], including polymorphisms in the genes controlling hepatic enzymes involved in the metabolism of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">
          "Clopidogrel resistance and clopidogrel treatment failure", section on 'Definitions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">
          "Clopidogrel resistance and clopidogrel treatment failure", section on 'Potential explanations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         or
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         in patients with ACS [
         <a href="#rid38">
          38,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of uncovered stent struts (as detected by optical coherence tomography) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic kidney disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stent overlap.
        </p>
        <p>
        </p>
        <p>
         One study found the following risk factors for definite stent thrombosis in second-generation DES based on the timing of stent thrombosis [
         <a href="#rid40">
          40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early stent thrombosis:
         </strong>
         Current smoking, left ventricular ejection fraction &lt;40 percent, prior PCI, stent overlap, severely calcified lesion, left main coronary artery lesion, proximal left anterior descending lesion, and post-diameter stenosis ≥20 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late stent thrombosis:
         </strong>
         Age &lt;70 years, STEMI at presentation, hemodialysis, left ventricular ejection fraction &lt;40 percent, in-stent restenosis, and severely calcified lesion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Very late stent thrombosis:
         </strong>
         Proximal left anterior descending lesion and in-stent restenosis.
        </p>
        <p>
        </p>
        <p>
         Although stent location probably does not increase the risk of stent thrombosis occurrence, stent location in the left main or proximal left anterior descending artery poses increased risk of an adverse outcome if stent thrombosis occurs and may be regarded as an indication for more aggressive prevention strategies.
        </p>
        <p>
         Gastrointestinal bleeding is a risk of DAPT, and routine proton pump inhibitors are recommended in patients at higher risk for bleeding. Some studies have raised the possibility that some proton pump inhibitors interfere with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         's ability to inhibit platelet function due to interference with conversion to active metabolite. This issue is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">
          "Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention", section on 'Prevention'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Bleeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/35.html" rel="external">
          "NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Very late stent thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The specific risk factors for very late stent thrombosis are less well defined but relate to delayed neointimal coverage and ongoing vessel inflammation [
         <a href="#rid49">
          49,58
         </a>
         ]. A probable explanation for an increased risk of thrombosis in first generation DES compared with bare metal stent (BMS) after cessation of antiplatelet therapy is delayed arterial healing, particularly incomplete neointimal coverage. However, rates of very late stent thrombosis with newer generation DES, such as everolimus-eluting stent or RESOLUTE-zotarolimus-eluting stent, are lower than earlier generation DES and possibly lower than BMS.
        </p>
        <p>
         Documentation of very late stent thrombosis has come from real-time imaging studies using either angioscopy or optical coherence tomography (OCT), from postmortem examination of stented segments in patients with and without stent thrombosis, or from the histology of in-stent restenosis tissue obtained by atherectomy.
        </p>
        <p>
         An angioscopic study of 37 consecutive stented lesions (15
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         stents and 22 BMS) showed that neointimal coverage is not complete in most patients with SES, but complete with all BMS at three to six months [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Delayed neointimal coverage in patients with SES was confirmed in a longer-term study of 17 SES and 11 BMS in which angioscopy was performed at 4, 10, and 21 months [
         <a href="#rid26">
          26
         </a>
         ]. There were two main findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neointimal coverage was complete in all but one of the patients with BMS at 3.6 months and in all at 10 months. In contrast, the majority of patients with SES had incomplete coverage at 21 months
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mural red thrombi were seen only in patients with SES and incomplete neointimal coverage
        </p>
        <p>
        </p>
        <p>
         Angioscopy is limited in the evaluation of the extent of neointimal coverage since it cannot quantify the proportion or thickness of coverage. These limitations are not present with OCT, an intravascular imaging technique that visualizes the surface of a stent with higher resolution than intravascular ultrasound (IVUS) [
         <a href="#rid59">
          59,60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16536.html" rel="external">
          "Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation", section on 'Optical coherence tomography'
         </a>
         .)
        </p>
        <p>
         The mechanisms underlying very late DES thrombosis were explored using OCT in a study of 64 registry patients. In this study, very late stent thrombosis occurred at a median of 4.7 years [
         <a href="#rid60">
          60
         </a>
         ]. The leading associated findings in descending order were malapposition, neoatherosclerosis, uncovered struts, and stent underexpansion. These associations were similar in early- and new-generation DES.
        </p>
        <p>
         These findings are consistent with those in two postmortem studies and analysis of atherectomy specimens [
         <a href="#rid49">
          49,58,61
         </a>
         ]. A postmortem study compared 28 stented segments with thrombus to 34 without thrombus in 46 patients who died more than 30 days after DES implantation [
         <a href="#rid49">
          49
         </a>
         ]. The most powerful histologic predictor of stent thrombosis was incomplete endothelial coverage (uncovered struts).
        </p>
        <p>
         Similar findings were noted in the second postmortem study in which delayed arterial healing was more pronounced in 14 DES patients with late stent thrombosis than in nine patients without stent thrombosis [
         <a href="#rid58">
          58
         </a>
         ]. In addition, patients with DES had a greater degree of delayed arterial healing and less complete re-endothelialization than patients with BMS.
        </p>
        <p>
         Current smoking and total stent length &gt;28 mm have been identified as risk factors for very late stent thrombosis [
         <a href="#rid34">
          34
         </a>
         ]. Whether these play a role by influencing the rate of arterial healing is not known.
        </p>
        <p>
         In-stent neoatherosclerosis has also been seen in many cases of very late stent thrombosis. Neoatherosclerosis in stents, similar to native coronary vessels, is characterized by macrophage-mediated degradation of collagen with necrotic core formation that predisposes to plaque rupture and thrombosis. In BMS, neoatherosclerosis rarely occurs before three years and is more common in those greater than six years old [
         <a href="#rid62">
          62
         </a>
         ]. In DES, neoatherosclerosis is accelerated and can be a cause of thrombosis in stents less than two years after implantation [
         <a href="#rid63">
          63
         </a>
         ]. The frequency of neoatherosclerosis development appears similar for first and second generation DES but may be associated with fewer unstable features with second generation devices [
         <a href="#rid64">
          64
         </a>
         ]. The factors that predispose to development of neoatherosclerosis are unknown but may involve dysfunctional endothelium.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Other issues related to risk
         </span>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          On-label versus off-label use
         </span>
         <span class="headingEndMark">
          —
         </span>
         The randomized trials demonstrating the lower rate of restenosis with DES compared to BMS were performed in patients with single, previously untreated coronary lesions (on-label use). In the SIRIUS trial, for example, the exclusion criteria included ostial, bifurcation, and unprotected left main lesions, and vessels with thrombus or severe calcification; in addition, multivessel stenting was not performed and patients with a recent MI or a left ventricular ejection fraction (LVEF) less than 25 percent were excluded [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         There has been concern whether the risk and timing of stent thrombosis (ST) may be different for these excluded or so-called off-label indications (more complex disease). At least two studies have suggested that the risk of ST in patients who received BMS or DES for off-label indications is higher than for those with on-label indications at both early and later time points [
         <a href="#rid66">
          66,67
         </a>
         ]. This is not surprising, as the baseline risk of patients with off-label indications is higher. For example, these individuals often have an acute coronary syndrome.
        </p>
        <p>
         In previous, smaller studies, each of the more common off-label indications was found to be associated with an increased risk of stent thrombosis. These include multivessel stenting [
         <a href="#rid68">
          68
         </a>
         ], bifurcation stenting [
         <a href="#rid41">
          41,69-72
         </a>
         ], particularly with use of the crush technique [
         <a href="#rid71">
          71,72
         </a>
         ], chronic total occlusions, and in-stent restenosis [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">
          "Percutaneous coronary intervention of specific coronary lesions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1587.html" rel="external">
          "Intracoronary stent restenosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Nonanatomic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of non-coronary clinical factors are also associated with stent thrombosis. These include diabetes mellitus [
         <a href="#rid9">
          9,41,47,69
         </a>
         ], being a Black person [
         <a href="#rid73">
          73
         </a>
         ], chronic kidney disease [
         <a href="#rid41">
          41,69
         </a>
         ], acute coronary syndrome at presentation [
         <a href="#rid9">
          9
         </a>
         ], cocaine use [
         <a href="#rid74">
          74,75
         </a>
         ], elevated C-reactive protein levels [
         <a href="#rid76">
          76
         </a>
         ], and, in rare cases, a hypersensitivity reaction to the stent [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="local">
          'Impact of ACS'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">
          "Periprocedural complications of percutaneous coronary intervention", section on 'Hypersensitivity reactions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Incomplete stent apposition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incomplete stent apposition, also known as stent mal-apposition, is defined as the absence of stent strut contact with the underlying vessel wall (not overlying a side branch) [
         <a href="#rid78">
          78
         </a>
         ]. This phenomenon, which is identified by intravascular ultrasound (IVUS) or optical coherence tomography, can occur at the time of stent implantation; it may resolve or worsen. It may also occur late (up to years) and in this setting has been attributed either to positive remodeling (an increase in vessel diameter) whereby the vessel pulls away from the stent, or to plaque or thrombus dissolution, such that a space forms between the stent and the vessel wall.
        </p>
        <p>
         Two IVUS studies support an association between late incomplete stent apposition and very late stent thrombosis in patients with DES:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 13 patients with very late stent thrombosis and 144 controls, incomplete stent apposition was significantly more frequent in patients (77 versus 12 percent) than controls [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 23 patients with DES and seven with BMS very late stent thrombosis, stent malapposition was seen in 74 percent of DES but none of the BMS patients [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          COMPARISON OF DES AND BMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both randomized trial and observational study data have demonstrated that the cumulative rate of stent thrombosis is similar for bare metal and the first generation drug-eluting stents (SES and PES) at up to five years [
         <a href="#rid11">
          11,80
         </a>
         ].
        </p>
        <p>
         Similarly, the rate of early stent thrombosis is comparable between BMS and SES or PES. There may be a slight predominance of BMS ST between 30 days and one year (late ST) and a slight preponderance of DES stent thrombosis beyond one year (very late stent thrombosis), particularly for early generation DES such as SES and PES [
         <a href="#rid30">
          30
         </a>
         ]. There have been no randomized trials comparing second generation DES, such as everolimus-eluting stents (EES) or RESOLUTE-zotarolimus-eluting stents (R-ZES), that were large enough to be sufficiently powered to determine the relative rates of stent thrombosis between BMS and EES or R-ZES.
        </p>
        <p>
         The relative rates of stent thrombosis between DES and BMS have been compared in meta-analyses. We advise caution in the interpretation of their conclusions, due to the relatively short duration of follow-up and the fact that the patients included in the trials are representative of only a portion of all patients treated with coronary artery stents.
        </p>
        <p>
         Two large meta-analyses are referred to in the sections below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2012 comprehensive network meta-analysis that included 49 randomized trials (over 50,000 patients) and compared one DES to a BMS or to another DES  (
         <a class="graphic graphic_table graphicRef65603" href="/z/d/graphic/65603.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid81">
          81
         </a>
         ]. The primary endpoint in this meta-analysis was the one year rate of definite stent thrombosis according to Academic Research Consortium (ARC) criteria (see
         <a class="local">
          'Definitions'
         </a>
         above).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefit of this network meta-analysis is that indirect comparisons between DES that have not been directly compared in a randomized trial, but have been compared with a third stent, can be made [
         <a href="#rid82">
          82
         </a>
         ]. However, our confidence is not high that comparisons made in this meta-analysis are representative due to the concerns about non-contemporaneous comparisons and other potential sources of bias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2012 analysis (Bangalore) of 77 randomized trials (of SES, PES, EES, ZES, and ZES-Resolute) with over 57,000 patients [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Late and one-year cumulative stent thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall risk of stent thrombosis at up to one year is low for both BMS and DES as long as patients are continued on dual antiplatelet therapy with both
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and platelet P2Y
         <sub>
          12
         </sub>
         receptor blocker for the recommended duration [
         <a href="#rid84">
          84,85
         </a>
         ]. (See
         <a class="local">
          'Timing and incidence'
         </a>
         above.)
        </p>
        <p>
         Studies comparing early generation DES (SES or PES) to BMS suggested that the risk of stent thrombosis at up to one year was comparable [
         <a href="#rid24">
          24,29,86
         </a>
         ].
        </p>
        <p>
         In the 2012 network meta-analysis, the rates of late definite stent thrombosis of SES, PES, and ZES were comparable to BMS; however, the rate was significantly lower with the CoCr-EES compared to BMS (odds ratio 0.27) [
         <a href="#rid81">
          81
         </a>
         ]. Since only two of the studies in the meta-analysis directly compared CoCr-EES to BMS, this finding should not be considered definitive. Changes in the design of BMS over time and other unmeasured factors may have influenced the indirect comparison of CoCr-EES to BMS in this study more so than with earlier generation DES. In the larger 2012 meta-analysis (Bangalore), similar findings were noted, including a lower rate with EES (56 percent lower) compared to BMS [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Very late and cumulative long-term stent thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Very late stent thrombosis includes events after one year, while the cumulative rate of stent thrombosis includes all events. The rate of very late stent thrombosis with DES between one and four years is approximately 0.6 percent with the protocol definition [
         <a href="#rid1">
          1
         </a>
         ] and approximately 0.9 percent with the ARC definition [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="local">
          'Timing and incidence'
         </a>
         above.)
        </p>
        <p>
         Meta-analyses using the ARC definitions of definite or probable stent thrombosis have concluded that there is no significant difference in the cumulative rate (at two or more years) of stent thrombosis between older DES (either SES or PES) and BMS [
         <a href="#rid1">
          1,30,84,86-88
         </a>
         ]. However, some [
         <a href="#rid1">
          1,9,87,89
         </a>
         ] but not all studies [
         <a href="#rid30">
          30,58,81
         </a>
         ] have suggested that the rates of very late stent thrombosis are higher with these first generation DES.
        </p>
        <p>
         The two large 2012 meta-analyses evaluated the rates of stent thrombosis at two years [
         <a href="#rid81">
          81,83
         </a>
         ]. In the network meta-analysis, EES (CoCr-EES) had a significantly lower cumulative rate of stent thrombosis compared to BMS (odds ratio 0.35, 95% CI 0.17-0.69) [
         <a href="#rid81">
          81
         </a>
         ]. The Bangalore meta-analysis came to a similar conclusion [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          COMPARISON OF DIFFERING DES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Not all types of drug-eluting stents (DES) have been directly compared. The evidence suggests that use of newer generation DES leads to lower rates of stent thrombosis compared to older DES. Most of the data are for the everolimus-eluting stent (EES). There is less information available for R-ZES, but it is possible they also have lower rates than older DES. Potential factors responsible for lower rates of stent thrombosis with newer DES include more bio-compatible polymers, newer stent designs with thinner struts, and lower drug dose.
        </p>
        <p>
         Some evidence suggests that the rate of stent thrombosis with bioresorbable polymer DES (see
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types", section on 'Bioresorbable polymer drug-eluting stents'
         </a>
         ) is similar to that with current-generation durable polymer DES [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H616228991">
         <span class="h2">
          Late and cumulative one-year stent thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         With regard to late definite stent thrombosis, EES of both types outperformed older E-ZES and PES, but not SES. With regard to cumulative one-year definite stent thrombosis (the primary composite outcome), the following significant odds ratios (OR) were noted (other comparisons between SES, PES, the two types of EES, and the two types of ZES did not achieve statistical significance) [
         <a href="#rid81">
          81
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CoCr-EES versus PES 0.28 (0.16-0.48)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CoCr-EES versus SES 0.41 (0.24-0.70)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CoCr-EES versus Re-ZES 0.14 (0.03-0.47)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CoCr-EES versus PC-ZES 0.21 (0.10-0.44)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PC-ZES versus SES 1.92 (1.07-3.90)
        </p>
        <p>
        </p>
        <p>
         Similar findings of a lower rate of any stent thrombosis with EES, compared to SES, PES, and ZES, were found in the Bangalore meta-analysis [
         <a href="#rid83">
          83
         </a>
         ]. No significant differences in the rates of stent thrombosis at one year were found in paired comparisons between other DES.
        </p>
        <p class="headingAnchor" id="H283851917">
         <span class="h2">
          Very late stent and cumulative two-year thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some [
         <a href="#rid91">
          91-93
         </a>
         ], but not all [
         <a href="#rid30">
          30,86,94
         </a>
         ], studies comparing rates of stent thrombosis between SES and PES after one year found lower rates with SES.
        </p>
        <p>
         The current body of evidence from randomized trials suggests that long-term cumulative rates of stent thrombosis are lower with EES than SES or PES. There is some evidence to suggest this is also true for R-ZES:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the comprehensive network meta-analysis of randomized trials discussed above [
         <a href="#rid81">
          81
         </a>
         ], no significant differences in the rates of definite stent thrombosis comparing one DES (two types of EES, two types of ZES, SES, and PES) to another at two years with one exception: the odds ratio comparing cobalt CoCr-EES to PES was significant (0.34, 95% CI 0.19-0.62). A significant risk reduction remained when the analysis evaluated two-year definite or probable stent thrombosis. Similar findings were noted in the Bangalore meta-analysis of randomized trials [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2012 meta-analysis of 11 trials (16,775 patients) that compared the risk of two-year definite stent thrombosis between EES and SES (five trials), PES (five trials) or R-ZES (one trial), the risk of definite stent thrombosis with EES compared with pooled DES occurred in 0.5 percent versus 1.3 percent of patients (relative risk 0.38, 95% CI 0.24-0.59) [
         <a href="#rid8">
          8
         </a>
         ]. This translated into a 0.6 percent absolute risk reduction in favor of EES [
         <a href="#rid95">
          95
         </a>
         ]. Similar results were obtained using the broader definition of definite or probable stent thrombosis. On further analysis, the lower risk with EES was found for early, late, cumulative one-year, and very late events.
        </p>
        <p>
        </p>
        <p>
         The finding of a lower rate of long-term stent thrombosis with EES compared to first generation stents is supported by observational studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 12,339 patients who received SES, PES, or EES, the cumulative incidence rate of definite stent thrombosis during four years of follow-up was lower with EES compared with PES or SES (adjusted hazard ratios 0.33, 95% CI 0.23-0.48 and 0.41, 95% CI 0.27-0.62, respectively) [
         <a href="#rid96">
          96
         </a>
         ]. These findings remained significant for the analysis of definite or probable stent thrombosis. Differences in the rates of stent thrombosis were due mostly to a lower risk of stent thrombosis beyond one year (very late stent thrombosis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2012 report from SCAAR in which newer DES (EES and Resolute ZES) were compared to older DES (SES, PES, and, according to their classification, Endeavor ZES), the cumulative risk of definite stent thrombosis at two years was lower with newer DES (adjusted hazard ratio 0.57, 95% CI 0.41-0.79) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a 2012 prospective observational study of 6166 unselected patients who received either EES or SES, the rates of stent thrombosis at two years were similar (hazard ratio 1.16, 95% CI 0.47-2.84, comparing EES to SES) [
         <a href="#rid97">
          97
         </a>
         ].Rates of stent thrombosis between EES and R-ZES have been evaluated in the RESOLUTE All Comers and TWENTE randomized trials, neither of which was powered to detect differences in these rates [
         <a href="#rid98">
          98,99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types", section on 'Everolimus- versus zotarolimus-eluting stents'
         </a>
         .) In these two trials, the rates of definite or probable stent thrombosis were low and not significantly different in the two groups at one year or later. In a pooled analysis of studies with the R-ZES including 7618 patients, the five-year rate of stent thrombosis was 1.2 percent with an annual rate of 0.1 percent for very late stent thrombosis.
        </p>
        <p>
         In a study of 8791 patients who were randomly assigned to either E-ZES (an older version of ZES) or a SES, the rates of definite or probable stent thrombosis were similar at three years (1.4 versus 1.8 percent) [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing and incidence
         </strong>
         – Stent thrombosis is an uncommon but potentially life-threatening complication of the placement of an intracoronary stent. While it can occur at any time after stent placement, the majority of events occur within the first month irrespective of stent type. Stent thrombosis with bare metal stents (BMS) or drug-eluting stents (DES) has been observed as long as five years after stent placement. The presentation is often with MI, usually with ST elevation, or death. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Timing and incidence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – The premature cessation of dual antiplatelet therapy is the most important risk factor for ST. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The cumulative rates of ST at one year are comparable between BMS and most DES (with the possible exception of everolimus-eluting stents [EES], for which the rate is likely lower). (See
         <a class="local">
          'Late and one-year cumulative stent thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         At two years, the cumulative rate of ST is approximately 1.5 to 2 percent, and similar for both BMS and first generation DES. It is likely that this risk is lower for EES. (See
         <a class="local">
          'Very late and cumulative long-term stent thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The cumulative long-term risk of ST appears comparable among all DES, except for possibly higher risk for PES and lower risk for EES. Given potential differences between DES for the period beyond two years, longer-term follow-up is needed. (See
         <a class="local">
          'Very late stent and cumulative two-year thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comparison of differing DES
         </strong>
         – Data are limited to make inferences regarding the risk of stent thrombosis for RESOLUTE-zotarolimus-eluting stents (R-ZES), but available data suggest the long-term risk is similar for R-ZES and EES. (See
         <a class="local">
          'Comparison of differing DES'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation 2018; 137:2635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brener SJ, Cristea E, Kirtane AJ, et al. Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv 2013; 6:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014; 63:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chieffo A, Bonizzoni E, Orlic D, et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004; 109:2732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagerqvist B, Carlsson J, Fröbert O, et al. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2009; 2:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53:1399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schühlen H, Kastrati A, Pache J, et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001; 37:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leon MB, Wong SC. Intracoronary stents. A breakthrough technology or just another small step? Circulation 1994; 89:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton JM, Ellis SG, Roubin GS, et al. Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation 1994; 89:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003; 108:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno R, Fernández C, Hernández R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheller B, Hennen B, Pohl A, et al. Acute and subacute stent occlusion; risk-reduction by ionic contrast media. Eur Heart J 2001; 22:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 2007; 49:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47:2108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Awata M, Kotani J, Uematsu M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007; 116:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013; 6:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roiron C, Sanchez P, Bouzamondo A, et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faxon DP. Very late stent thrombosis and late target lesion revascularization: no end in sight. Circulation 2012; 125:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen LO, Tilsted HH, Thayssen P, et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010; 5:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012; 125:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tandjung K, Sen H, Lam MK, et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 2013; 61:2406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoki J, Lansky AJ, Mehran R, et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2009; 119:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation 2009; 119:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012; 172:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuramitsu S, Ohya M, Shinozaki T, et al. Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis. Circ Cardiovasc Interv 2019; 12:e007822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119:1634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira-González I, Marsal JR, Ribera A, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010; 122:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cayla G, Hulot JS, O'Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011; 306:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113:2803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura S, Colombo A, Gaglione A, et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994; 89:2026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg SL, Colombo A, Nakamura S, et al. Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents. J Am Coll Cardiol 1994; 24:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouman HJ, van Werkum JW, Breet NJ, et al. A case-control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost 2011; 9:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013; 128:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv 2012; 5:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumoto D, Shite J, Shinke T, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007; 28:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Circulation 2016; 133:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Beusekom HM, Saia F, Zindler JD, et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 2007; 28:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamaji K, Inoue K, Nakahashi T, et al. Bare metal stent thrombosis and in-stent neoatherosclerosis. Circ Cardiovasc Interv 2012; 5:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 2014; 129:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297:1992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez AE, Mieres J, Fernandez-Pereira C, et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol 2006; 47:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005; 46:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams DO, Abbott JD. Bifurcation intervention: is it crush time yet? J Am Coll Cardiol 2005; 46:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 2010; 122:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemos PA. Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis? Catheter Cardiovasc Interv 2007; 69:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKee SA, Applegate RJ, Hoyle JR, et al. Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J 2007; 154:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009; 120:1987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115:2426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CW, Kang SJ, Park DW, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol 2010; 55:1936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisz G, Leon MB, Holmes DR Jr, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009; 53:1488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ormiston JA, Webster MW. Stent thrombosis: has the firestorm been extinguished? Lancet 2012; 379:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005; 45:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caixeta A, Leon MB, Lansky AJ, et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kereiakes DJ, Meredith IT, Windecker S, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. Circ Cardiovasc Interv 2015; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaltoft A, Jensen LO, Maeng M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 2009; 53:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schömig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galløe AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008; 299:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanini GG, Windecker S. Stent thrombosis: no longer an issue with newer-generation drug-eluting stents? Circ Cardiovasc Interv 2012; 5:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Räber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park DW, Kim YH, Song HG, et al. Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study. Circ Cardiovasc Interv 2012; 5:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silber S, Windecker S, Vranckx P, et al. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011; 377:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012; 380:1396.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1582 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296824" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470709" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical end points in coronary stent trials: a case for standardized definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29891620" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23266233" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24184169" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15148281" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325255" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22668554" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17321312" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031749" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19371823" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9834303" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11419889" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11306525" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8041414" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8124824" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intracoronary stents. A breakthrough technology or just another small step?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8041413" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8124799" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8996288" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12821553" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766835" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15680728" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207080" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acute and subacute stent occlusion; risk-reduction by ionic contrast media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17349883" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16697331" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17684153" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22232428" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24355117" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16216853" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Drug eluting stents: an updated meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296821" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Stent thrombosis in randomized clinical trials of drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22203695" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Very late stent thrombosis and late target lesion revascularization: no end in sight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18804739" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20542774" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22203694" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23602769" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19171852" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19204315" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Early stent thrombosis: past, present, and future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18377975" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22529227" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31177822" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15870416" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24004642" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19204304" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289638" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733100" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22028352" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16534015" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16769908" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17438147" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8181126" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intracoronary ultrasound observations during stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7930236" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7882474" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17224480" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228612" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21382172" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A case-control study on platelet reactivity in patients with coronary stent thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23900047" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22230145" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16814667" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17135281" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26762519" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17434882" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22253359" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Bare metal stent thrombosis and in-stent neoatherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21376502" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24163064" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14523139" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488964" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Outcomes and complications associated with off-label and untested use of drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488965" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16386687" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16490815" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766834" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16098424" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16098425" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Bifurcation intervention: is it crush time yet?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20805432" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17525956" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17584570" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19884467" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16386683" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17485593" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20430265" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19389558" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22445239" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22445240" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Stent thrombosis: has the firestorm been extinguished?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22586281" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296822" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766833" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16106007" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296825" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19712798" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296823" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25855680" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19232897" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17869634" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17903638" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18230778" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22715449" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Stent thrombosis: no longer an issue with newer-generation drug-eluting stents?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22302840" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22693347" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21459430" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20554978" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22951082" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
